A Phase 2 interventional study of PF-04965842 and PF-04965842 in Plaque Psoriasis, sponsored by Pfizer. Terminated at 45 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-05.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Psoriasis by Pfizer — none open to participants now, none under way, none of them phase 3. Psoriasis · Pfizer.
Among the 57 studies in Psoriasis by Pfizer, this one is the 32nd largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2014, is one of 13 in phase 2, and was the 47th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →None of the 57 studies in Psoriasis by Pfizer is open now. The open studies under Psoriasis, anywhere →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 120 across the 42 interventional studies, 458 across the 15 observational. Of the 56 that completed or were terminated, 46 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Psoriasis by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis. The study will include three PF-04965842 groups (200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. The treatment period will be 4 weeks in duration and will be followed up by a 4 week follow up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Within 9 months of first dose of study drug:
Within 12 weeks of first dose of study drug:
Within 4 8 weeks of first dose of study drug:
Within 4 weeks of first dose of study drug:
Within 2 weeks of first dose of study drug:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200mg of PF-04965842 twice daily
Drug: PF-04965842
400mg of PF-04965842 once daily
Drug: PF-04965842
200mg of PF-04965842 once daily
Drug: PF-04965842
Placebo comparator daily
Other: Placebo
Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks
Also known as: JAK1 inhibitor
Subjects will receive 400 mg PF 04965842 daily for 4 weeks
Also known as: JAK1 inhibitor
Subjects will receive 200 mg PF 04965842 daily for 4 weeks
Also known as: JAK1 inhibitor
Subjects will receive placebo for 4 weeks
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 4
PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).
Time frame: Baseline, Week 4
Percent Change From Baseline in PASI Score at Week 1, 2, 3, 4, 5, 6, and 8
PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).
Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8
Change From Baseline in PASI Score at Week 1, 2, 3, 5, 6 and 8
PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).
Time frame: Baseline, Week 1, 2, 3, 5, 6, 8
Percentage of Participants Achieving 50 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6, and 8
PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 50 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.
Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8
Percentage of Participants Achieving 75 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6 and 8
PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 75 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.
Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8
Percentage of Participants Achieving 90 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6, and 8
PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 90 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.
Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)
Percentage of Participants Achieving Physician Global Assessment (PGA) Response of 'Clear' or 'Almost Clear' at Week 1, 2, 3, 4, 5, 6, and 8
The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema (E), induration (I), and scaling (S) across all psoriatic lesions. The severity rating scores (erythema: 0= no evidence of erythema to 4= dark, deep red; Induration: 0= no evidence of plaque elevation to 4= marked plaque elevation, hard/sharp borders; Scaling: 0= no evidence of scaling to 4= thick, coarse scale predominates) were summed (E + I + S= total) and the average (total/3) was taken. The total average was rounded to the nearest whole number score to determine the PGA. The 5-point scale for PGA was: 0= clear; 1= almost clear; 2= mild; 3= moderate; 4= severe, where higher score indicating more severity. Participants with response of clear and almost clear were reported. 90 percent confidence intervals were calculated using clopper-pearson (exact) method.
Time frame: Week 1, 2, 3, 4, 5, 6, 8
Change From Baseline in Fasting Lipids at Week 2, 4 and 8
Participants were required to fast 9 hours prior to sampling for lipid profile which included following parameters: low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), cholesterol, triglycerides.
Time frame: Baseline, Week 2, 4, 8 (early termination)
Change From Baseline in Lipid Ratios at Week 2, 4 and 8
The ratio of LDL-C/HDL-C was reported.
Time frame: Baseline, Week 2, 4, 8 (early termination)
Change From Baseline in High Sensitivity C- Reactive Protein (hsCRP) at Week 1, 2, 3, 4, and 8
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Reference range for measurements is 0-0.5 mg/dL and lower limit of detection is less than (\<) 0.015 mg/dL. Any value \<0.015 mg/dL is imputed as 0.0075 mg/dL.
Time frame: Baseline, Week 1, 2, 3, 4, 8 (early termination)
Number of Participants Reporting Clinically Significant Change From Baseline in Epstein-Barr Virus (EBV) Values
EBV samples were collected and changes from baseline were evaluated by the principal investigator (PI) for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in adverse event (AEs) or required follow-up.
Time frame: Baseline up to Week 8 (early termination)
Number of Participants Reporting Clinically Significant Change From Baseline in Cytomegalovirus (CMV) Values
CMV samples were collected and changes from baseline were evaluated by the PI for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in AEs or required follow-up.
Time frame: Baseline up to Week 8 (early termination)
Number of Participants Reporting Clinically Significant Change From Baseline in Herpes Simplex Virus Deoxyribonucleic Acid (HSV DNA) Values
HSV DNA samples were collected and changes from baseline were evaluated by the PI for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in AEs or required follow-up.
Time frame: Baseline up to Week 8 (early termination)
Change From Baseline in Blood Pressure (BP) at Week 1, 2, 3, 4, 5, 6, and 8
Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)
Change From Baseline in Pulse Rate at Week 1, 2, 3, 4, 5, 6, and 8
Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)
Change From Baseline in Respiratory Rate at Week 1, 2, 3, 4, 5, 6, and 8
Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)
Change From Baseline in Body Temperature at Week 1, 2, 3, 4, 5, 6, and 8
Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)
Number of Participants Reporting Clinically Significant Change From Baseline in Heart Rate
Time frame: Baseline up to Week 8 (early termination)
Number of Participants Reporting Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters
ECG change data was reported as qualitative results, as per change in planned analysis. It was categorized as: normal; abnormal, not clinically significant or abnormal, clinically significant.
Time frame: Baseline up to Week 8 (early termination)
| Milestone | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Started | 14 | 15 | 16 | 14 |
| Completed | 12 | 12 | 12 | 10 |
| Not completed | 2 | 3 | 4 | 4 |
| Withdrew: Adverse event | 0 | 2 | 1 | 0 |
| Withdrew: Insufficient clinical response | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 0 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 |
| Withdrew: Other | 1 | 1 | 0 | 0 |
PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).
| units on a scale | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Baseline (n= 14, 15, 16, 14) | 20.05 ± 3.993 | 20.34 ± 7.089 | 19.21 ± 4.426 | 18.01 ± 5.507 |
| Change at Week 4 (n= 12, 12, 12, 10) | -6.61 ± 7.252 | -11.73 ± 6.658 | -13.09 ± 7.979 | -13.71 ± 6.248 |
PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).
| percent change | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Change at Week 1 (n= 14, 15, 16, 14) | -13.68 ± 18.527 | -23.27 ± 18.796 | -24.07 ± 22.272 | -30.99 ± 28.557 |
| Change at Week 2 (n= 14, 14, 13, 12) | -26.68 ± 25.776 | -27.96 ± 20.161 | -41.54 ± 28.779 | -49.09 ± 30.153 |
| Change at Week 3 (n= 13, 12, 15, 11) | -27.06 ± 31.220 | -33.96 ± 19.793 | -53.18 ± 33.326 | -73.37 ± 22.569 |
| Change at Week 4 (n= 12, 12, 12, 10) | -33.59 ± 31.574 | -57.61 ± 21.594 | -64.46 ± 32.175 | -80.96 ± 23.155 |
| Change at Week 5 (n= 11, 12, 12, 9) | -42.62 ± 21.228 | -58.63 ± 16.015 | -57.76 ± 37.397 | -80.80 ± 20.279 |
| Change at Week 6 (n= 11, 11, 10, 10) | -39.85 ± 28.661 | -61.02 ± 11.655 | -56.94 ± 39.558 | -69.15 ± 26.871 |
| Change at Week 8 (n= 8, 11, 11, 8) | -44.62 ± 26.616 | -44.28 ± 27.486 | -48.63 ± 35.373 | -61.67 ± 29.352 |
PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).
| units on a scale | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Change at Week 1 (n= 14, 15, 16, 14) | -2.96 ± 4.306 | -5.13 ± 4.902 | -4.79 ± 4.900 | -5.46 ± 4.965 |
| Change at Week 2 (n= 14, 14, 13, 12) | -5.26 ± 5.205 | -5.80 ± 4.915 | -8.33 ± 7.103 | -8.51 ± 5.860 |
| Change at Week 3 (n= 13, 12, 15, 11) | -5.38 ± 7.033 | -7.44 ± 5.824 | -10.77 ± 8.048 | -12.61 ± 4.461 |
| Change at Week 5 (n= 11, 12, 12, 9) | -8.69 ± 5.314 | -11.68 ± 5.262 | -11.77 ± 8.421 | -14.17 ± 6.483 |
| Change at Week 6 (n= 11, 11, 10, 10) | -8.05 ± 6.989 | -12.00 ± 4.901 | -12.13 ± 9.576 | -11.80 ± 6.678 |
| Change at Week 8 (n= 8, 11, 11, 8) | -9.33 ± 6.745 | -8.38 ± 4.933 | -10.04 ± 8.287 | -10.75 ± 6.382 |
PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 50 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.
| percentage of participants | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Week 1 (n= 14, 15, 16, 14) | 7.1 (0.4 to 29.7) | 6.7 (0.3 to 27.9) | 25.0 (9.0 to 48.4) | 21.4 (6.1 to 46.6) |
| Week 2 (n= 14, 14, 13, 12) | 21.4 (6.1 to 46.6) | 7.1 (0.4 to 29.7) | 23.1 (6.6 to 49.5) | 41.7 (18.1 to 68.5) |
| Week 3 (n= 13, 12, 15, 11) | 23.1 (6.6 to 49.5) | 25.0 (7.2 to 52.7) | 46.7 (24.4 to 70.0) | 90.9 (63.6 to 99.5) |
| Week 4 (n= 12, 12, 12, 10) | 25.0 (7.2 to 52.7) | 66.7 (39.1 to 87.7) | 66.7 (39.1 to 87.7) | 80.0 (49.3 to 96.3) |
| Week 5 (n= 11, 12, 12, 9) | 54.5 (27.1 to 80.0) | 66.7 (39.1 to 87.7) | 58.3 (31.5 to 81.9) | 100.0 (71.7 to 100) |
| Week 6 (n= 11, 11, 10, 10) | 45.5 (20.0 to 72.9) | 81.8 (53.0 to 96.7) | 60.0 (30.4 to 85.0) | 70.0 (39.3 to 91.3) |
| Week 8 (n= 8, 11, 11, 8) | 50.0 (19.3 to 80.7) | 45.5 (20.0 to 72.9) | 63.6 (35.0 to 86.5) | 62.5 (28.9 to 88.9) |
PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 75 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.
| percentage of participants | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Week 1 (n= 14, 15, 16, 14) | 0.0 (0.0 to 19.3) | 0.0 (0.0 to 18.1) | 0.0 (0.0 to 17.1) | 7.1 (0.4 to 29.7) |
| Week 2 (n= 14, 14, 13, 12) | 7.1 (0.4 to 29.7) | 0.0 (0.0 to 19.3) | 15.4 (2.8 to 41.0) | 25.0 (7.2 to 52.7) |
| Week 3 (n= 13, 12, 15, 11) | 7.7 (0.4 to 31.6) | 0.0 (0.0 to 22.1) | 40.0 (19.1 to 64.0) | 36.4 (13.5 to 65.0) |
| Week 4 (n= 12, 12, 12, 10) | 16.7 (3.0 to 43.8) | 16.7 (3.0 to 43.8) | 50.0 (24.5 to 75.5) | 60.0 (30.4 to 85.0) |
| Week 5 (n= 11, 12, 12, 9) | 0.0 (0.0 to 23.8) | 25.0 (7.2 to 52.7) | 50.0 (24.5 to 75.5) | 66.7 (34.5 to 90.2) |
| Week 6 (n= 11, 11, 10, 10) | 18.2 (3.3 to 47.0) | 9.1 (0.5 to 36.4) | 60.0 (30.4 to 85.0) | 50.0 (22.2 to 77.8) |
| Week 8 (n= 8, 11, 11, 8) | 25.0 (4.6 to 60.0) | 9.1 (0.5 to 36.4) | 18.2 (3.3 to 47.0) | 25.0 (4.6 to 60.0) |
PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 90 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.
| percentage of participants | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Week 1 (n= 14, 15, 16, 14) | 0.0 (0.0 to 19.3) | 0.0 (0.0 to 18.1) | 0.0 (0.0 to 17.1) | 7.1 (0.4 to 29.7) |
| Week 2 (n= 14, 14, 13, 12) | 7.1 (0.4 to 29.7) | 0.0 (0.0 to 19.3) | 7.7 (0.4 to 31.6) | 8.3 (0.4 to 33.9) |
| Week 3 (n= 13, 12, 15, 11) | 0.0 (0.0 to 20.6) | 0.0 (0.0 to 22.1) | 13.3 (2.4 to 36.3) | 36.4 (13.5 to 65.0) |
| Week 4 (n= 12, 12, 12, 10) | 0.0 (0.0 to 22.1) | 0.0 (0.0 to 22.1) | 33.3 (12.3 to 60.9) | 60.0 (30.4 to 85.0) |
| Week 5 (n= 11, 12, 12, 9) | 0.0 (0.0 to 23.8) | 0.0 (0.0 to 22.1) | 25.0 (7.2 to 52.7) | 44.4 (16.9 to 74.9) |
| Week 6 (n= 11, 11, 10, 10) | 0.0 (0.0 to 23.8) | 0.0 (0.0 to 23.8) | 20.0 (3.7 to 50.7) | 30.0 (8.7 to 60.7) |
| Week 8 (n= 8, 11, 11, 8) | 0.0 (0.0 to 31.2) | 0.0 (0.0 to 23.8) | 0.0 (0.0 to 23.8) | 25.0 (4.6 to 60.0) |
The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema (E), induration (I), and scaling (S) across all psoriatic lesions. The severity rating scores (erythema: 0= no evidence of erythema to 4= dark, deep red; Induration: 0= no evidence of plaque elevation to 4= marked plaque elevation, hard/sharp borders; Scaling: 0= no evidence of scaling to 4= thick, coarse scale predominates) were summed (E + I + S= total) and the average (total/3) was taken. The total average was rounded to the nearest whole number score to determine the PGA. The 5-point scale for PGA was: 0= clear; 1= almost clear; 2= mild; 3= moderate; 4= severe, where higher score indicating more severity. Participants with response of clear and almost clear were reported. 90 percent confidence intervals were calculated using clopper-pearson (exact) method.
| percentage of participants | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Week 1 (n= 14, 15, 16, 14) | 0.0 (0.0 to 19.3) | 13.3 (2.4 to 36.3) | 12.5 (2.3 to 34.4) | 7.1 (0.4 to 29.7) |
| Week 2 (n= 14, 14, 13, 12) | 7.1 (0.4 to 29.7) | 28.6 (10.4 to 54.0) | 23.1 (6.6 to 49.5) | 41.7 (18.1 to 68.5) |
| Week 3 (n= 13, 12, 15, 11) | 15.4 (2.8 to 41.0) | 33.3 (12.3 to 60.9) | 46.7 (24.4 to 70.0) | 45.5 (20.0 to 72.9) |
| Week 4 (n= 12, 12, 12, 10) | 16.7 (3.0 to 43.8) | 41.7 (18.1 to 68.5) | 58.3 (31.5 to 81.9) | 70.0 (39.3 to 91.3) |
| Week 5 (n= 11, 12, 12, 9) | 27.3 (7.9 to 56.4) | 33.3 (12.3 to 60.9) | 41.7 (18.1 to 68.5) | 77.8 (45.0 to 95.9) |
| Week 6 (n= 11, 11, 10, 10) | 36.4 (13.5 to 65.0) | 45.5 (20.0 to 72.9) | 40.0 (15.0 to 69.6) | 50.0 (22.2 to 77.8) |
| Week 8 (n= 8, 11, 11, 8) | 25.0 (4.6 to 60.0) | 27.3 (7.9 to 56.4) | 45.5 (20.0 to 72.9) | 37.5 (11.1 to 71.1) |
Participants were required to fast 9 hours prior to sampling for lipid profile which included following parameters: low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), cholesterol, triglycerides.
| milligram per deciliter (mg/dL) | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Baseline: (n= 14, 15. 16, 14) | 119.07 ± 24.780 | 105.27 ± 28.632 | 114.56 ± 28.317 | 113.93 ± 31.770 |
| LDL-C: Change at Week 2 (n= 13, 14, 14, 12) | -6.31 ± 16.825 | 18.50 ± 31.035 | 3.21 ± 25.097 | 26.92 ± 24.748 |
| LDL-C: Change at Week 4 (n= 12, 12, 12, 10) | -2.50 ± 11.350 | 26.75 ± 26.455 | 10.17 ± 22.143 | 15.20 ± 30.904 |
| LDL-C: Change at Week 8 (n= 7, 11, 10, 8) | 7.14 ± 20.659 | 6.00 ± 16.529 | -3.20 ± 12.072 | -15.13 ± 20.301 |
| HDL-C: Baseline (n= 14, 15, 16, 14) | 52.93 ± 12.640 | 46.47 ± 11.230 | 49.06 ± 15.058 | 50.29 ± 10.163 |
| HDL-C: Change at Week 2 (n= 13, 14, 14, 12) | -1.54 ± 7.881 | 10.00 ± 5.533 | 10.64 ± 9.295 | 14.00 ± 8.113 |
| HDL-C: Change at Week 4 (n= 12, 12, 12, 10) | -1.00 ± 6.238 | 9.25 ± 6.717 | 12.25 ± 10.437 | 12.80 ± 10.075 |
| HDL-C: Change at Week 8 (n= 7, 11, 10, 8) | -2.43 ± 10.737 | -2.36 ± 2.730 | -0.40 ± 6.275 | -5.00 ± 6.234 |
| Cholesterol: Baseline (n= 14, 15, 16, 14) | 195.43 ± 30.137 | 186.80 ± 25.741 | 188.75 ± 32.298 | 191.14 ± 36.469 |
| Cholesterol: Change at Week 2 (n= 13, 14, 14 12) | -0.77 ± 14.800 | 29.57 ± 31.329 | 21.00 ± 34.005 | 44.08 ± 23.469 |
| Cholesterol: Change at Week 4 (n= 12, 12, 12, 10) | -3.50 ± 20.174 | 40.08 ± 25.062 | 27.25 ± 22.919 | 26.40 ± 29.220 |
| Cholesterol: Change at Week 8 (n= 7, 11, 10, 8) | 9.86 ± 24.361 | 7.45 ± 14.733 | -1.20 ± 20.395 | -10.88 ± 23.991 |
| Triglycerides: Baseline (n= 14, 15, 16, 14) | 116.64 ± 47.490 | 175.00 ± 74.971 | 125.50 ± 50.552 | 134.21 ± 53.903 |
| Triglycerides: Change at Week 2 (n= 13, 14, 14 12) | 35.85 ± 49.173 | 23.79 ± 72.638 | 35.86 ± 47.337 | 15.83 ± 43.151 |
| Triglycerides: Change at Week 4 (n=12, 12, 12, 10) | 0.67 ± 42.470 | 35.67 ± 80.714 | 24.00 ± 66.766 | -7.30 ± 44.144 |
| Triglycerides: Change at Week 8 (n= 7, 11, 10, 8) | 48.71 ± 102.301 | 41.09 ± 68.405 | 12.20 ± 44.434 | 46.50 ± 62.198 |
The ratio of LDL-C/HDL-C was reported.
| ratio | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| LDL-C: HDL C; Baseline (n= 14,15,16,14) | 2.35 ± 0.745 | 2.39 ± 0.915 | 2.48 ± 0.735 | 2.37 ± 0.912 |
| LDL-C: HDL C; Change at Week 2 (n=13,14,14,12) | 0.02 ± 0.449 | -0.05 ± 0.593 | -0.33 ± 0.384 | -0.03 ± 0.367 |
| LDL C: HDL C; Change at Week 4 (n= 12, 12, 12, 10) | 0.01 ± 0.218 | 0.11 ± 0.552 | -0.30 ± 0.468 | -0.07 ± 0.813 |
| LDL C: HDL C; Change at Week 8 (n=7,11,10, 8) | 0.37 ± 0.381 | 0.32 ± 0.439 | -0.07 ± 0.324 | -0.04 ± 0.362 |
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Reference range for measurements is 0-0.5 mg/dL and lower limit of detection is less than (\<) 0.015 mg/dL. Any value \<0.015 mg/dL is imputed as 0.0075 mg/dL.
| mg/dL | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Baseline (n= 14, 15, 16, 14) | 0.6056 ± 1.05280 | 0.6718 ± 0.71527 | 0.3325 ± 0.28854 | 0.4994 ± 0.43345 |
| Change at Week 1 (n= 14, 15, 16, 14) | -0.1451 ± 0.37322 | -0.5495 ± 0.66033 | -0.2288 ± 0.26512 | -0.3807 ± 0.49723 |
| Change at Week 2 (n= 13, 14, 14, 12) | -0.1712 ± 0.49223 | -0.4540 ± 0.80459 | -0.1783 ± 0.27518 | -0.3374 ± 0.49736 |
| Change at Week 3 (n= 12, 12, 15, 11) | 0.0323 ± 0.61746 | 1.2447 ± 5.21627 | -0.0471 ± 0.45332 | -0.2214 ± 0.48102 |
| Change at Week 4 (n= 11, 12, 12, 10) | -0.0284 ± 0.64387 | -0.4093 ± 0.83169 | 0.1162 ± 0.95838 | -0.0850 ± 0.63410 |
| Change at Week 8 (n= 7, 11, 11, 8) | -0.5996 ± 1.17921 | -0.2473 ± 0.94249 | 0.2521 ± 0.53698 | -0.0081 ± 0.16782 |
EBV samples were collected and changes from baseline were evaluated by the principal investigator (PI) for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in adverse event (AEs) or required follow-up.
| participants | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Number of Participants Reporting Clinically Significant Change From Baseline in Epstein-Barr Virus (EBV) Values | 0 | 0 | 0 | 0 |
CMV samples were collected and changes from baseline were evaluated by the PI for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in AEs or required follow-up.
| participants | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Number of Participants Reporting Clinically Significant Change From Baseline in Cytomegalovirus (CMV) Values | 0 | 0 | 0 | 0 |
HSV DNA samples were collected and changes from baseline were evaluated by the PI for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in AEs or required follow-up.
| participants | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Number of Participants Reporting Clinically Significant Change From Baseline in Herpes Simplex Virus Deoxyribonucleic Acid (HSV DNA) Values | 0 | 0 | 0 | 0 |
| millimeter of mercury (mmHg) | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Systolic BP: Baseline (n= 14,15,16,14) | 125.4 ± 11.77 | 125.5 ± 11.46 | 124.7 ± 12.97 | 128.0 ± 11.50 |
| Systolic BP: Change at Week 1 (n= 14, 15, 16, 14) | -2.1 ± 9.64 | -1.5 ± 10.94 | 0.6 ± 8.87 | 2.0 ± 10.88 |
| Systolic BP: Change at Week 2 (n= 13, 13, 14, 10) | -0.3 ± 6.73 | -1.6 ± 9.46 | 3.9 ± 8.01 | -0.4 ± 7.68 |
| Systolic BP: Change at Week 3 (n= 12, 12, 14, 10) | -4.5 ± 7.09 | -3.3 ± 7.82 | 6.7 ± 16.82 | -1.0 ± 13.65 |
| Systolic BP: Change at Week 4 (n= 12, 12, 12, 10) | -2.3 ± 5.66 | -5.8 ± 12.40 | 0.2 ± 7.44 | 1.7 ± 15.44 |
| Systolic BP: Change at Week 5 (n= 11, 12, 12, 9) | -2.9 ± 9.98 | -0.8 ± 8.29 | -0.3 ± 10.37 | 2.0 ± 18.08 |
| Systolic BP: Change at Week 6 (n= 11, 12, 12, 10) | -5.7 ± 8.95 | -1.3 ± 7.99 | -2.0 ± 8.86 | -0.2 ± 11.37 |
| Systolic BP: Change at Week 8 (n= 14, 14, 13, 13) | -2.3 ± 12.96 | -2.1 ± 9.61 | -2.1 ± 7.12 | 3.5 ± 11.49 |
| Diastolic BP: Baseline (n=14,15,16,14) | 77.1 ± 7.39 | 76.5 ± 6.84 | 77.4 ± 9.85 | 79.9 ± 10.73 |
| Diastolic BP: Change at Week 1 (n=14,15,16,14) | 0.0 ± 6.88 | 0.9 ± 6.97 | 0.8 ± 9.99 | 2.0 ± 10.02 |
| Diastolic BP: Change at Week 2 (n=13,13,14,10) | 0.6 ± 8.08 | 1.5 ± 8.96 | -0.4 ± 9.13 | 2.5 ± 6.08 |
| Diastolic BP: Change at Week 3 (n=12,12,14,10) | -0.7 ± 8.17 | -0.9 ± 7.50 | 1.1 ± 7.76 | 0.3 ± 10.70 |
| Diastolic BP Change at Week 4 (n=12,12,12,10) | -2.5 ± 8.21 | -2.3 ± 6.61 | 1.2 ± 5.46 | 2.4 ± 9.58 |
| Diastolic BP: Change at Week 5 (n= 11, 12, 12, 9) | 0.8 ± 5.13 | 0.0 ± 5.64 | 0.4 ± 5.62 | 1.8 ± 10.32 |
| Diastolic BP: Change at Week 6 (n=11,12,12,10) | 0.5 ± 5.91 | 2.1 ± 6.36 | -2.8 ± 5.67 | 0.9 ± 7.49 |
| Diastolic BP: Change at Week 8 (n= 14,14,13,13) | -1.1 ± 8.12 | -0.6 ± 6.08 | 1.5 ± 9.77 | 1.4 ± 9.26 |
| beats per minute (bpm) | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Baseline (n= 14, 15, 16, 14) | 67.6 ± 7.87 | 71.8 ± 11.85 | 72.2 ± 11.54 | 72.6 ± 9.64 |
| Change at Week 1 (n= 14, 15, 16, 14) | 1.0 ± 6.50 | -0.2 ± 8.51 | 0.0 ± 10.56 | -4.3 ± 7.43 |
| Change at Week 2 (n= 13, 13, 14, 10) | 2.8 ± 9.97 | -4.7 ± 9.39 | -2.4 ± 8.50 | -2.8 ± 8.48 |
| Change at Week 3 (n= 12, 12, 14, 10) | 4.1 ± 15.09 | -1.3 ± 10.76 | -1.5 ± 11.06 | -2.3 ± 6.88 |
| Change at Week 4 (n= 12, 12, 12, 10) | -1.3 ± 9.69 | -1.3 ± 12.89 | -4.7 ± 10.87 | 0.5 ± 9.37 |
| Change at Week 5 (n= 11, 12, 12, 9) | 5.2 ± 12.75 | 2.7 ± 10.44 | -0.8 ± 10.34 | 7.8 ± 11.11 |
| Change at Week 6 (n= 11, 12, 12, 10) | 4.5 ± 12.36 | -1.8 ± 11.46 | 2.4 ± 8.53 | 4.7 ± 9.15 |
| Change at Week 8 (n= 14, 14, 13, 13) | 0.9 ± 11.96 | -0.6 ± 13.87 | -5.3 ± 11.29 | -1.2 ± 8.12 |
| respiration per minute (resp/min) | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Baseline (n= 14, 15, 16, 13) | 16.2 ± 1.58 | 17.1 ± 3.67 | 16.3 ± 2.44 | 17.0 ± 2.16 |
| Change at Week 1 (n= 14, 15, 16, 13) | -0.5 ± 1.70 | 0.9 ± 1.98 | -0.1 ± 0.81 | -0.3 ± 1.60 |
| Change at Week 2 (n= 13, 13, 14, 9) | -0.5 ± 1.45 | 0.4 ± 1.71 | -0.6 ± 1.82 | 0.7 ± 2.65 |
| Change at Week 3 (n= 12, 12, 14, 9) | -0.3 ± 0.87 | -0.6 ± 1.51 | -0.4 ± 1.69 | 0.2 ± 1.56 |
| Change at Week 4 (n= 12, 12, 12, 9) | 0.2 ± 2.12 | -0.7 ± 1.72 | -1.2 ± 1.75 | 0.0 ± 1.41 |
| Change at Week 5 (n= 11, 12, 12, 8) | 0.1 ± 1.45 | 0.3 ± 2.30 | -0.9 ± 1.78 | -0.6 ± 1.92 |
| Change at Week 6 (n= 11, 12, 12, 9) | -0.4 ± 0.81 | 0.2 ± 1.34 | -0.8 ± 1.54 | -0.2 ± 1.20 |
| Change at Week 8 (n= 14, 14, 13, 12) | -0.3 ± 1.49 | -0.2 ± 2.01 | -0.8 ± 1.30 | -1.0 ± 1.60 |
| degree celsius | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Baseline (n= 14, 15, 16, 14) | 36.49 ± 0.363 | 36.59 ± 0.274 | 36.67 ± 0.282 | 36.57 ± 0.433 |
| Change at Week 1 (n= 14, 15, 16, 14) | -0.01 ± 0.264 | -0.03 ± 0.322 | 0.00 ± 0.265 | -0.17 ± 0.271 |
| Change at Week 2 (n= 13, 13, 14, 10) | -0.04 ± 0.366 | -0.22 ± 0.397 | -0.05 ± 0.509 | -0.05 ± 0.273 |
| Change at Week 3 (n= 12, 12, 14, 10) | -0.04 ± 0.391 | -0.21 ± 0.510 | -0.11 ± 0.287 | 0.09 ± 0.501 |
| Change at Week 4 (n= 12, 12, 12, 10) | -0.07 ± 0.467 | -0.21 ± 0.362 | -0.02 ± 0.346 | -0.12 ± 0.477 |
| Change at Week 5 (n= 11, 12, 12, 9) | 0.21 ± 0.316 | 0.07 ± 0.318 | 0.01 ± 0.305 | 0.13 ± 0.443 |
| Change at Week 6 (n= 10, 12, 12, 10) | 0.05 ± 0.328 | -0.00 ± 0.292 | -0.07 ± 0.269 | 0.00 ± 0.390 |
| Change at Week 8 (n= 14, 14, 13, 13) | 0.10 ± 0.332 | -0.01 ± 0.361 | -0.05 ± 0.326 | 0.07 ± 0.426 |
| bpm | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Number of Participants Reporting Clinically Significant Change From Baseline in Heart Rate | 0 | 0 | 0 | 0 |
ECG change data was reported as qualitative results, as per change in planned analysis. It was categorized as: normal; abnormal, not clinically significant or abnormal, clinically significant.
| participants | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Number of Participants Reporting Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters | 0 | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/14 (7.1%) | 6/14 (42.9%) |
| PF-04965842 200 Milligram (mg) Once Daily | — | 0/15 (0%) | 7/15 (46.7%) |
| PF-04965842 400 mg Once Daily | — | 0/16 (0%) | 14/16 (87.5%) |
| PF-04965842 200 mg Twice Daily | — | 0/14 (0%) | 11/14 (78.6%) |
| Event | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| Transient ischaemic attackNervous system disorders | 1/14 | 0/15 | 0/16 | 0/14 |
| Event | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily |
|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/14 | 0/15 | 0/16 | 5/14 |
| HeadacheNervous system disorders | 2/14 | 1/15 | 5/16 | 1/14 |
| NauseaGastrointestinal disorders | 1/14 | 2/15 | 4/16 | 3/14 |
| NeutropeniaBlood and lymphatic system disorders | 1/14 | 0/15 | 1/16 | 3/14 |
| Platelet count decreasedInvestigations | 0/14 | 0/15 | 1/16 | 3/14 |
| ContusionInjury, poisoning and procedural complications | 1/14 | 0/15 | 0/16 | 2/14 |
| White blood cell count decreasedInvestigations | 0/14 | 1/15 | 0/16 | 2/14 |
| HypertensionVascular disorders | 0/14 | 0/15 | 2/16 | 1/14 |
| LeukopeniaBlood and lymphatic system disorders | 0/14 | 0/15 | 0/16 | 1/14 |
| White blood cell disorderBlood and lymphatic system disorders | 1/14 | 0/15 | 0/16 | 0/14 |
The full analysis set (FAS) included all randomized participants who received at least 1 dose of the randomized study drug (PF-04965842 or placebo).
| Age, Continuous(years) | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily | Total |
|---|---|---|---|---|---|
| Mean | 45.4 ± 10.8 | 42.9 ± 12.3 | 42.8 ± 11.6 | 52.1 ± 9.7 | 45.7 ± 11.5 |
| Sex: Female, Male(Participants) | Placebo | PF-04965842 200 Milligram (mg) Once Daily | PF-04965842 400 mg Once Daily | PF-04965842 200 mg Twice Daily | Total |
|---|---|---|---|---|---|
| Female | 3 | 5 | 5 | 6 | 19 |
| Male | 11 | 10 | 11 | 8 | 40 |
The record gives a start of Nov 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrocitinib